Last reviewed · How we verify
NCT06907082: Her-Database
Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma®) in Early HER2-positive Breast Cancer in Routine Clinical Practice
NA trial testing Combination of pertuzumab and the trastuzumab biosimilar CT-P6 (Herzuma®) in Her2-positive breast cancer susceptible to neoadjuvant chemotherapy. in Breast Cancer in 106 participants. Completed in 14 March 2024.
14 March 2024
Quick facts
| Lead sponsor | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 106 |
| Start date | 28 December 2020 |
| Primary completion | 14 March 2024 |
| Estimated completion | 14 March 2024 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Combination of pertuzumab and the trastuzumab biosimilar CT-P6 (Herzuma®) in Her2-positive breast cancer susceptible to neoadjuvant chemotherapy.
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia — full company profile →
Who can join
18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study hypothesis is to evaluate whether the pCR rate of neoadjuvant chemotherapy and dual blockade with pertuzumab and the trastuzumab biosimilar CT-P6 (Herzuma®) in HER2-positive early breast cancer in PCH is similar to that reported in clinical trials. Other aspects to be analyzed include the safety of the combination in PCH, as well as the clinical and tumor characteristics of the study population, assessment of radiological and pathological response, and the role of treatment-induced immunogenicity and the value of plasma HER2 determination.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Translational and real-world evidence of trastuzumab biosimilar CT-P6 plus pertuzumab in neoadjuvant HER2-positive early breast cancer.
Alonso-Romero JL, Martínez-García J, Carrillo-Vicente R, Aramburo AF, et al · · 2026 · PMID 41557021 · DOI 10.1007/s10549-026-07895-8 -
Translational and Real-World Evidence of Trastuzumab Biosimilar CT-P6 Plus Pertuzumab in Neoadjuvant HER2-Positive Early Breast Cancer
Alonso-Romero JL, Martínez-García J, Carrillo-Vicente R, Aramburo AF, et al · · 2025 · DOI 10.21203/rs.3.rs-8020339/v1
Verify or expand the search:
- PubMed search for NCT06907082
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia trials
Trials by the same sponsor.
- NCT07064811 — Standardized Resistance Training Program and Assessment System for Prostate Cancer Patients Receiving Androgen Deprivati · NA · not yet recruiting
- NCT06646562 — Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged ≥ 60 Years for 24 Months. · Phase 4 · recruiting
- NCT06874907 — First Trimester Prediction of Gestational Diabetes Mellitus by Continuous Glucose Monitoring. · recruiting
- NCT06858345 — Study of Maternal and Fetal Cardiovascular Function in Hypertensive States of Pregnancy · recruiting
- NCT06713486 — Efficacy of Self-titration of Ventilation in Overlap Syndrome (chronic Obstructive Pulmonar Disease + Sleep Apnea Syndro · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06907082 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
- Last refreshed: 2 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06907082.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing